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Abstract
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis 
(RA) synovial membranes. High levels have been detected in the synovial fluid of patients w ith RA. 
The trigger for IL-17 is not fully identified; however, IL-23 promotes the production of IL-17 and a 
strong correlation between IL-15 and IL-17 levels in synovial fluid has been observed. IL-17 is a 
potent inducer of various cytokines such as tumor necrosis factor (TNF)-a, IL-1, and receptor 
activator of NF-kB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-a in 
inducing cytokine expression and joint damage have been shown in vitro and in vivo. This review 
describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in 
vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant 
when T cells are a major element of the arthritis process. Moreover, IL-17 has the capacity to induce 
joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17 
cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in 
situations in which elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy.
Keywords autoimmune diseases, cytokine, inflammation, interleukin-23, osteoclast, receptor activator of NF-k B 
ligand
Interleukin-17 and family members
Interleukin-17 (IL-17) is a 17 kDa protein that is secreted 
as a dimer by a restricted set of cells, predominantly 
activated human memory T cells or mouse apTCR+CD4- 
CD8-  thymocytes [1 -3 ]. Rouvier and colleagues have 
cloned cytotoxic T lymphocyte-associated antigen-8 (rat 
IL-17) from a T cell subtraction library [4] and mouse IL-17 
was cloned from a thymus-derived, activated T cell cDNA 
library [3]. Subsequently, the human counterpart of mouse 
IL-17 was cloned by two independent groups [1,2,5]. 
Human IL-17 has 25% amino acid sequence homology to 
mouse IL-17, as well as 72% homology to an open- 
reading frame from the T lymphotropic herpes virus saimiri 
(HVS13) and 63% homology to CTLA8 [2,4]. In addition 
to IL-17 (IL-17A) another five members of the IL-17 family 
have been discovered (IL-17B-F) by large-scale
sequencing of the human and other vertebrate genomes 
(Table 1) [6].
The different IL-17 family members seem to have very 
distinct expression patterns, suggesting distinct biological 
roles. IL-17B is moderately expressed in several peripheral 
tissues as well as immune tissues [7,8], and IL-17E is 
expressed in various peripheral tissues [9]. Interestingly, 
IL-17F has biological functions similar to those of IL-17(A) 
and is also produced by activated monocytes [10,11]. 
This indicates that the IL-17 family might contribute to the 
pathology of rheumatoid arthritis (RA) and other 
inflammatory diseases not only through activated T cells 
but also through activated monocytes/macrophages. 
Further work will be required to determine the precise 
mechanism of action of IL-17 and its family members such
CIA =  collagen-induced arthritis; CII =  type II collagen; IL =  interleukin; MMP =  matrix metalloproteinase; PMN =  polymorphonuclear cell; RA = 
rheumatoid arthritis; RANKL =  receptor activator of NF-kB ligand; TNF =  tumor necrosis factor. 29
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Table 1
Interleukin (IL)-17 fam ily  members and the ir receptors
Ligand Receptor Refs
IL-17 (IL-17A) IL-17R (IL-17AR) [5,11]
IL-17B IL-17BR (IL-17RH1/IL-17ER) (low affinity) [7,8,18]
IL-17C ? [7]
IL-17D ? [80]
IL-17E IL-17ER (IL-17RH1/IL-17BR) (high affinity) [9,18]
IL-17F IL-17R + ? [10,11]
? IL-17RL (IL-17RC) [17,18]
as IL-17F, IL-17B, and IL-17E in the development of 
chronic synovitis and tissue destruction during arthritis, 
especially in relation to other known key cytokines (IL-1, 
tumor necrosis factor [TNF], and receptor activator of 
NF-kB ligand [RANKL]).
IL-17 signaling
In contrast to the restricted expression of IL-17, the IL-17 
receptor (IL-17R) is ubiquitously expressed in virtually all 
cells and tissues. It is a type I transmembrane protein that 
has no sequence similarity to any other known cytokine 
receptor [5]. The exact mechanisms of IL-17 signaling are 
not fully elucidated. Binding of IL-17 to its unique receptor 
results in activation of the adapter molecule TNF-receptor- 
associated factor 6 (TRAF6), which is required for IL-1 7 
signaling [12]. IL-17 shares transcriptional pathways with IL- 
1 and TNF. It can activate NF-kB and all three classes of 
mitogen-activated protein (MAP) kinases including 
extracellular signal-related kinase (ERK)1 and ERK2, c-Jun 
N-terminal kinase (JNK), and p38 [13-15]. These pathways 
have been identified in synoviocytes [16] and chondrocytes
[14]. Four other receptors for the IL-17 family have been 
identified so far: IL-17RH1 [8] and IL-17RL (receptor-like)
[17], IL-17RD, and IL-17RE, which share partial sequence 
homology to IL-17R [18] (Table 1). The expression pattern 
of these new receptors seems to be more cell/tissue- 
specific than that of the IL-17R, and the ligand specificities 
of many of these receptors have not been established.
Regulation of IL-17
The physiological stimulus for the induction of IL-17 
expression has not been fully identified. Microbial stimuli 
induced the expression of IL-17 together with TNF-a in 
both murine and human T cells [19]. Cell-cell contact of 
human T cells with fibroblasts resulted in increased mRNA 
expression of IL-17 and IL-17R. Supernatants obtained 
from cell-cell contact-stimulated peripheral blood lympho­
cytes enhance the production of IL-6 and IL-8 by 
fibroblast-like synoviocytes, an effect that was blocked by 
30 antibodies against IL-17 [20]. Furthermore, IL-15 produced
by synoviocytes is considered to be a potent inducer of 
IL-17 production [21,22]. Moreover, IL-23 produced by 
activated DCs and macrophages acts on memory T cells, 
promoting the production of IL-17 (both IL-17 and IL-17F)
[23]. In addition, a direct role was suggested for IL-23 in 
IL-17 production by CD8+ T cells [23,24]. IL-23 affects 
memory T cell and inflammatory macrophage function, and 
IL-23 (but not IL-12) is a critical factor in autoimmune 
inflammation to the central nervous system [25].
Further support for IL-23 as an important trigger for IL-17 
was obtained from studies with IL-23-specific knockout 
mice [26,27]. Specific absence of IL-23 completely 
prevented collagen-induced arthritis (CIA), whereas loss 
of IL-12 exacerbates CIA [26]. Interestingly, resistance 
was correlated with an absence of IL-17-producing CD4+ 
T cells despite normal induction of collagen-specific, 
interferon-y-producing T helper 1 cells. In contrast, IL-12- 
deficient p35-deficient mice developed more IL-17- 
producing CD4+ T cells, as well as an elevated expression 
of proinflammatory cytokines (such as TNF-a, IL-1 p, IL-6, 
and IL-17) in affected tissues of diseased mice [26]. 
Importantly, IL-23-deficient mice resemble IL-17-deficient 
mice phenotypically [27,28]. These studies indicate the 
existence of an IL-23/IL-17 axis of communication between 
the innate and adaptive parts of the immune system that 
might be an interesting target for the immunotherapy of 
inflammatory autoimmune diseases [26,27].
Role of IL-17 in the pathogenesis of RA
RA is a chronic systemic disorder that is characterized by 
autoimmunity, infiltration of joint synovium by activated 
inflammatory cells, synovial hyperplasia, neoangiogenesis 
and progressive destruction of cartilage and bone. RA is 
considered to be a systemic Th1-associated inflammatory 
joint disease, and T cells comprise a large proportion of 
the inflammatory cells invading the synovial tissue. T cell 
activation and migration into the synovium occur as an 
early consequence of disease, and these cells adopt a 
pro-inflammatory phenotype. Considerable evidence now 
supports a role for T cells in the initiation and perpetuation 
of chronic inflammation prevalent in RA. Although T cells 
represent a large proportion of the inflammatory cells 
during inflammation, T cell-derived cytokines are much less 
abundant. However, because the vast majority of these are 
memory T cells, IL-17 is upregulated in early disease.
There is now considerable evidence from studies in vitro 
with RA synovium and/or co-cultures that IL-17 is a pro- 
inflammatory cytokine produced only by cells of the 
immune system, which is thought to contribute to 
inflammation associated with RA [29]. IL-17 is 
spontaneously produced by RA synovial membrane 
cultures, and IL-17-producing cells were found in T cell- 
rich areas [30] and high levels have been detected in the 
synovial fluid of patients with RA [21,30,31]. Although
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bioactive IL-17 is detected in RA and osteoarthritis 
synovial fluid, the levels of IL-17 were found to be higher in 
RA synovial fluid than in osteoarthritis synovial fluid 
[30,31]. The expression of IL-17 in Th 1 and Th2 cells 
seems to be different depending upon the conditions. 
Th1/Th0, but not Th2, subsets of CD4+ T cell clones 
isolated from rheumatoid synovium produced IL-17 [32]. 
In contrast, IL-17 production was found in both Th1 and 
Th2 clones from human skin-derived nickel-specific T cells
[33]. In mice, IL-17 is produced by T cells expressing 
TNF-a but not by Th1 or Th2 cells [19]. IL-17 stimulates 
transcriptional NF-kB activity and IL-6 and IL-8 secretion 
in fibroblastic, endothelial, and epithelial cells, and induces 
T cell proliferation [1,5]. Furthermore, it triggers human 
synoviocytes to produce granulocyte/macrophage colony- 
stimulating factor and prostaglandin E2 [1], suggesting 
that IL-17 could be an upstream mediator in the 
pathogenesis of arthritis and might have a function in fine- 
tuning the inflammatory response.
T cell IL-17 also stimulates the production of IL-1 and 
TNF-a from human PBMC-derived macrophages in vitro
[34]. It enhances IL-1-mediated IL-6 production by RA 
synoviocytes in vitro as well as TNF-a-induced synthesis 
of IL-1, IL-6, and IL-8 [35,36]. This indicates that IL-17 
synergizes with IL-1 and TNF, and it has been shown that 
the combination of TNF-a blockade with IL-1 and IL-17 
blockade is more effective for controlling IL-6 production 
in RA synovium cultures [37]. In addition, IL-17 induces 
RANKL expression, which is an essential cytokine for 
osteoclastogenesis and bone resorption [31]. IL-17 can 
synergize with these cytokines (IL-1, TNF, and RANKL), 
but probably acts directly as well. Furthermore, when IL- 
17 is combined with other cytokines that are already 
thought to be important in arthritic disease (such as TNF-a 
and IL-1), even more marked tissue destruction occurs 
[37] (Lubberts E, Koenders MI, Van den Berg WB, 
unpublished data). These observations strongly implicate 
IL-17 as having an important function in the disease 
pathogenesis of RA (Fig. 1).
Role of IL-17 in T cell immunity and/or 
propagation of joint inflammation
In arthritis, IL-17 is a pro-inflammatory cytokine thought to 
contribute to the joint inflammatory process [38]. Studies 
in IL-17-deficient mice revealed that IL-17 has an 
important function in the activation of T cells in allergen- 
specific T cell-mediated immune responses [28]. Further­
more, IL-17 has a function in the antigen-specific T cell 
activation phase of CIA [39]. O f interest, CIA was 
markedly but not completely suppressed in IL-17-deficient 
mice. IL-17 was responsible for the priming of collagen- 
specific T cells and for collagen-specific IgG2a production 
[39]. In contrast, the spontaneous development of 
destructive arthritis in mice deficient in IL-1 receptor 
antagonist could be completely prevented after
Figure 1
Schematic overview of interleukin-17 (IL-17) in relation to other key 
cytokines in the pathogenesis of arthritis. RANKL, receptor activator of 
NF-kB ligand; TNF, tumor necrosis factor.
inactivation of IL-17 [40]. In line with the situation in most 
RA patients, low systemic levels of IL-17 were found after 
the immunization protocol of CIA but IL-17 expression in 
the synovium gradually increased after the onset of CIA
[41]. Early neutralization of endogenous IL-17 using the IL- 
17 receptor IgG 1 Fc fusion protein starting after the 
immunization protocol during the initial phase of arthritis 
suppresses the onset of experimental arthritis [41]. 
Moreover, neutralizing endogenous IL-17 with anti-IL-17 
sera after the onset of CIA still diminished the severity of 
CIA [42]. Histological analysis confirmed the suppression 
of joint inflammation, and systemic IL-6 levels were 
significantly decreased after treatment with anti-IL-17 
antisera. In contrast, systemic as well as local IL-17 
overexpression using an adenoviral vector expressing 
murine IL-17 accelerated the onset of CIA and aggravated 
synovial inflammation at the site [41,43]. These 
observations strongly implicate a role for IL-17 at various 
levels in disease pathogenesis of arthritis. IL-17 seems to 
have a function in T cell immunity and in the propagation 
of joint inflammation.
Role of IL-17 in cartilage destruction
IL-17 has dual effects on cartilage. This T cell cytokine 
inhibits chondrocyte metabolism in intact articular 31
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cartilage of mice and induces proteoglycan breakdown 
(Table 2) [44-47 ]. Furthermore, studies in vitro showed 
the induction of metalloproteinases by IL-17 in 
synoviocytes and chondrocytes [48-50 ]. Interestingly, the 
IL-17 family subtypes IL-17F and IL-17E also showed 
cartilage destructive potential in vitro [11,47] (Table 2). 
Another IL-17 family member, IL-17B, has been shown to 
be expressed by chondrocytes in normal bovine articular 
cartilage, mostly in the mid and deep zones [18].
IL-17 shares biological activities with IL-1, which is a key 
cytokine in the induction of cartilage destruction [51]. In 
vitro, IL-17 suppresses matrix synthesis by articular 
chondrocytes through enhancement of nitric oxide 
production [45,52-54]. However, it has been shown that 
the effects of IL-17 on matrix degradation and synthesis 
were not dependent on IL-1 production by chondrocytes 
and IL-1Ra did not block IL-17-induced matrix release nor 
did they prevent the inhibition of matrix synthesis in vitro 
with pig articular cartilage explants [47]. In contrast, the 
IL-17-induced production of prostaglandin E2 and nitric 
oxide by cartilage explants is dependent on leukemia 
inhibitory factor [47,54]. Interestingly, an IL-1-independent 
role of IL-17 in the pathogenesis of experimental arthritis 
was demonstrated [41]. The downstream signaling 
pathways for IL-17 and IL-1 seem to be distinct, and 
differential activation of activator protein 1 (AP-1) 
members by IL-17 and IL-1 p has been described [49]. 
Although IL-1 is by far the more catabolic cytokine in 
experimental arthritis in comparison with TNF-a, the 
combination of IL-17 and TNF-a synergizes to induce 
cartilage destruction in vitro [55] as well as in vivo 
(Lubberts E, unpublished data). These data suggest that 
IL-17 alone or in combination with TNF-a might 
circumvent the catabolic effects of IL-1 on cartilage.
Interrelation between IL-17, 
polymorphonuclear cell influx, and cartilage 
destruction
In mice, local overexpression of IL-17 in the knee joint of 
both naive mice and mice immunized with type II collagen 
(CII) leads to enhanced influx of polymorphonuclear cells 
(PMNs) [41]. A main difference between IL-17 over­
expression in naive and CII-immunized DBA-1 mice was 
the observation that, in CIA, PMNs were heavily sticking to 
patella and femur cartilage, a phenomenon that was not 
observed in naive mice. Interestingly, under both 
conditions, local IL-17 induced proteoglycan depletion 
(Table 2). However, no chondrocyte death and cartilage 
erosion was observed in naive mice after local IL-17 gene 
transfer (Table 2). In contrast, local IL-17 aggravates 
cartilage erosion in CIA [41].
The lack of irreversible cartilage destruction under naive 
conditions in contrast to CIA conditions might be due to 
the lack of immune complexes formed during IL-17-
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induced joint inflammation in normal mice. Although IL-17 
overexpression induced enhanced synovial stromelysin 
(pro-matrix metalloproteinase [pro-MMP]-3) expression 
under naive as well as CIA conditions (Lubberts E, 
unpublished data), the presence of immune complexes 
might be required for the cleavage process of pro-MMPs 
into active MMPs. This phenomenon is not well under­
stood.
The elevated neutrophil influx and subsequent sticking to 
anti-CII immune complexes in the cartilage surface layer 
during CIA probably releases oxygen species and 
proteolytic enzymes present in PMNs directly into the 
surface of cartilage, thereby escaping inhibitors present in 
the synovial fluid [41,56,57]. IL-17 might enhance immune 
complex formation in CIA because IL-17 has a crucial 
function in activating autoantigen-specific cellular and 
humoral immune responses [39].
In contrast to aggravation of cartilage damage by IL-17 
overexpression, neutralizing endogenous IL-17 in arthritis 
models protects against cartilage destruction. Both 
reversible proteoglycan depletion and the irreversible 
cartilage markers chondrocyte death and cartilage surface 
erosion were suppressed after neutralizing IL-17 after the 
onset of CIA [42]. A reduced influx of PMNs was noted 
and fewer IL-1 p-positive cells were detected in the 
synovial infiltrate after treatment with anti-IL-17 antibody
[42]. Furthermore, the induction of chronic relapsing 
streptococcal cell wall-induced arthritis in mice deficient in 
the IL-17 receptor (IL-17R) revealed the critical role for T 
cell IL-17/IL-17R signaling in driving synovial IL-1 
expression and different metalloproteinases (Koenders MI, 
Kolls JK, Van den Berg W B, Lubberts E, unpublished 
data). These observations suggest that the presence of T 
cell IL-17 in the synovial infiltrate has major influences on 
PMN influx, synovial IL-1 expression, and the cartilage 
destructive process. IL-17 therefore seems to be a 
significant target for the treatment of cartilage destruction 
in T cell-mediated arthritis.
Role of IL-17 in bone erosion
In addition to the role of IL-17 in cartilage destruction, this 
T cell cytokine is a potent stimulator of osteoclastogenesis 
(Fig. 2). Promotion of type I collagen degradation in 
synovium and bone by IL-17 has been demonstrated, and 
when combined with IL-1, a marked synergistic release of 
collagen was noted [44]. IL-17 in combination with TNF-a 
increased osteoclastic resorption in vitro [58]. Further­
more, IL-17 induced the expression of RANKL in cultures 
of osteoblasts [31]. RANKL is a crucial regulator of 
osteoclastogenesis [59]. RANKL binds to its unique 
receptor activator of NF-kB (RANK) [60], and the RANKL/ 
RANK pathway seems of crucial importance in osteo- 
clastogenesis and the bone erosion process. RANKL and 
the decoy receptor osteoprotegerin [61] are important
Figure 2
Schematic overview of the mechanism of interleukin-17 (IL-17) in bone 
resorption. The interrelationship of IL-17 with receptor activator of 
NF-kB ligand (RANKL), IL-1, tumor necrosis factor (TNF) and the 
modulatory role of IL-4 and osteoprotegerin (OPG) is presented. OC, 
osteoclast.
positive and negative regulators of osteoclastogenesis 
and bone resorption. Regulation of IL-17 and RANKL, as 
shown by IL-4 gene therapy in collagen arthritis, prevents 
osteoclastogenesis and bone erosion [62]. Systemic 
treatment with a soluble IL-17 receptor fusion protein (sIL- 
17R:Fc) starting before arthritis expression in experimental 
arthritis prevented bone erosion [41,63]. Moreover, 
development of bone erosion in the chronic relapsing 
streptococcal cell wall-induced arthritis model in IL-17R- 
deficient mice was significantly suppressed (Lubberts E, 
Van den Berg WB, Kolls JK, unpublished data). In 
contrast, local IL-17 overexpression in the knee joint of CII- 
immunized mice resulted in promotion of collagen arthritis 
and aggravated joint destruction [43,64]. In the CIA model 
it was shown that IL-17 promoted bone erosion through 
loss of the RANKL/osteoprotegerin balance [64]. Systemic 
treatment with osteoprotegerin prevented joint damage 
induced by local IL-17 gene transfer in CII-immunized 
mice. This strongly suggests that IL-17 is a potent inducer 
of RANKL and that the IL-17-induced promotion of bone 
erosion is strongly mediated by RANKL.
Interrelation between IL-17 and IL-1/TNF
Overexpression of IL-17 in the mouse knee joint of CII- 
immunized mice resulted in elevated levels of IL-1 p protein 
in the synovium [41]. Intriguingly, blocking of IL-1 a/p with 
neutralizing antibodies had no effect on the IL-17-induced 
synovial inflammation and joint damage, implying an IL-1- 
independent pathway [41]. This direct potency of IL-17 
was underscored in the unabated IL-17-induced 
exaggeration of bacterial cell wall-induced arthritis in 
IL-1 p-deficient mice [41]. Apart from IL-1, synergistic 33
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effects between IL-17 and TNF in systems in vitro have 
been reported regarding cytokine induction and cartilage 
damage [44,55]. Because in mice IL-17-producing T cells 
also express TNF-a we performed blocking studies with 
IL-17 and TNF inhibitors. In line with the observations in 
vitro with RA synovial co-cultures [37], a combination 
blockade of TNF-a and IL-17 suppressed continuing CIA 
and was more effective than neutralizing TNF alone 
(Lubberts E, Van den Berg WB, unpublished data). It is of 
interest that TNF-a-dependent arthritis can be 
circumvented by IL-17 (Koenders MI, Lubberts E, Van den 
Berg WB, unpublished data). This underscores the 
potential of IL-17 to act additively or even synergistically 
with IL-1/TNF. Moreover, it also shows that T cell IL-17 
can replace the proinflammatory/catabolic function of IL-1/ 
TNF, directly or through interplay with other macrophage- 
driven factors.
Role of IL-17 in other 
inflammatory/autoimmune diseases
Apart from the role of IL-17 in autoimmune arthritis, IL-17 
and its family members exhibit a potential role in other 
inflammatory diseases, such as lung, gut, and skin 
inflammation [65-69 ]. IL-17 has a function in T-cell- 
triggered inflammation by stimulating stromal cells to 
secrete various cytokines and growth factors associated 
with inflammation [1,2]. IL-17 regulates gene expression 
and protein synthesis of the complement system [70]. It 
has a regulatory role on C3 expression and synthesis and 
an amplifying effect on TNF-induced factor B synthesis 
[70]. In addition, IL-17 stimulates granulopoiesis and is a 
strong inducer of neutrophil recruitment through chemo- 
kine release [65,71]. Furthermore, IL-17 promotes angio- 
genesis [72] and a role for IL-17 was suggested in 
allogeneic T cell proliferation that might be mediated in 
part through a maturation-inducing effect on dendritic 
cells (DC) [73]. Studies in IL-17-deficient mice revealed 
that this T cell cytokine had an important function in the 
activation of T cells in allergen-specific T cell-mediated 
immune responses [28]. IL-17 induced neutrophil 
accumulation in infected lungs. Greatly diminished recruit­
ment of neutrophils into lungs was found in mice with 
homozygous deletion of the IL-17 receptor in response to 
a challenge with a Gram-negative pathogen [74]. 
Overproduction of IL-17 has been associated with several 
chronic disease conditions, suggesting a role of IL-17 in 
these diseases. IL-17E transgenic mice showed growth 
retardation, jaundice, a Th2-biased response, and multi­
organ inflammation [75]. Furthermore, IL-17 expression 
was observed in ovarian, endometrial, and cervical 
cancers exhibiting angiogenic effects [76,77]. Elevated 
levels of IL-17 were found in other autoimmune diseases, 
such as experimental autoimmune encephalomyelitis [78], 
and in patients with systemic sclerosis [79]. However, 
further studies are needed to unravel the role of IL-17 in 
34 the pathogenesis of these autoimmune inflammations.
Conclusions
IL-17 is a T cell-derived cytokine produced by activated 
T cells, predominantly by activated CD4+CD45RO+ 
memory cells, and is expressed in the synovium of patients 
with RA. IL-17 has a function in T cell-triggered 
inflammation by stimulating different cell types to secrete 
various cytokines and chemokines. In addition, IL-17 
shows additive or even synergistic effects with IL-1 and 
TNF in inducing cytokine expression and joint pathology. 
Furthermore, T cell IL-17 is a potent inducer of RANKL, a 
crucial cytokine in osteoclastogenesis and bone resorption. 
IL-17 can act together with these cytokines but has direct 
pathological effects as well. It has been shown that IL-17 
has IL-1-independent activities in inducing synovial 
inflammation and joint destruction in experimental arthritis. 
Furthermore, IL-17 has a function in prolongation of the 
arthritis process and can be considered an important 
target for the treatment of destructive arthritis.
The discovery of IL-17 family members may further extend 
the role of this cytokine family in arthritis pathology. IL-17F 
showed similar biological effects to those of IL-17; 
however, IL-17F is expressed in activated monocytes in 
addition to activated T cells. Further studies will be 
required to determine the contribution and precise 
mechanism of action of the novel IL-17 family member(s), 
with emphasis on the interaction with other known key 
cytokines in the pathogenesis of arthritis. Furthermore, IL- 
23 seems to be an important physiological stimulus for the 
induction of IL-17 and IL-17F, although other mediators 
might also be involved [21,23,26,27].
Results so far suggest strongly that IL-17 is a novel target 
for the treatment of destructive arthritis. Because it is 
known that this T cell factor can have synergistic effects 
with catabolic/inflammatory mediators, it is tempting to 
speculate that IL-17 levels can influence whether or not a 
patient will respond to anti-TNF and anti-IL-1 therapy. Anti- 
IL-17 cytokine therapy might be an interesting new anti­
rheumatic approach that could contribute to the 
prevention of joint destruction as an adjunct to anti-TNF 
and anti-IL-1 therapy.
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